An antibacterial composition comprising salicylic acid and succinic acid

Abstract

In one embodiment, an antibacterial composition is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9. The composition exhibits superior antibacterial efficacy compared to a single component due to the synergistic effect between the two ingredients, particularly against acne-causing bacteria. Furthermore, when the composition is applied to acne-prone skin, it demonstrates preventative, alleviating, or therapeutic effects on acne-related symptoms without side effects.

Description

Technical Field

[0001] This relates to an antibacterial composition comprising salicylic acid and succinic acid. Background Technology

[0002] Acne is a common skin condition caused by clogged pores due to sebum, dead skin cells, and other impurities. It primarily affects teenagers, but can also occur in adults, appearing on the face, neck, chest, back, and other areas. Acne can be broadly categorized into whiteheads (horseshoe-shaped pimples), red papules (inflammatory red papules), and deeper cysts. Severity ranges from mild to severe, and in severe cases, it can cause not only skin problems but also psychological stress.

[0003] Salicylic acid, a representative ingredient, is widely used in acne-related products. It not only has anti-inflammatory effects but also softens and removes keratin that clogs pores and contributes to acne. However, when salicylic acid is applied to the skin in high concentrations to relieve acne, it can cause side effects such as dryness, itching, and erythema.

[0004] At the same time, it is known that succinic acid rarely causes the side effects such as dryness, itching, and erythema mentioned above.

[0005] Therefore, the inventors of this invention aim to provide an antibacterial composition comprising salicylic acid and succinic acid, and a patch comprising the same, to reduce the side effects of salicylic acid while achieving significantly superior acne prevention, improvement, or treatment. The composition exhibits significantly superior acne prevention, improvement, or treatment efficacy even when treated at concentrations lower than those of a single ingredient. Summary of the Invention

[0006] Technical problems to be solved In one embodiment, an antibacterial composition is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0007] In another embodiment, a pharmaceutical composition for the prevention or treatment of bacterial or fungal skin infections is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0008] In another embodiment, an antibacterial cosmetic composition is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0009] In another embodiment, an antibacterial topical skin agent is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0010] In another embodiment, a multilayer patch is provided, comprising: an antibacterial layer containing salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; and A coating is provided on the first surface of the antibacterial layer and comprises thermoplastic polyurethane (TPU).

[0011] Technical solutions to the problem In one embodiment, an antibacterial composition is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0012] Specifically, the antibacterial composition may comprise salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7, or 1:1.7 to 1.9.

[0013] When the antibacterial composition contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, it exhibits a significantly superior antibacterial effect through synergistic action compared to using a single component alone. Specifically, it shows an antibacterial effect against acne-causing bacteria, and when applied to acne-prone skin, acne symptoms are significantly reduced. On the other hand, when the antibacterial composition contains salicylic acid and succinic acid in a weight ratio less than 1:1, the antibacterial effect is significantly reduced, and when applied to acne-prone skin, side effects such as itching and redness caused by salicylic acid increase. When the weight ratio of salicylic acid and succinic acid exceeds 1:1.9, the antibacterial effect is significantly reduced.

[0014] In one specific example, the salicylic acid may be included in the composition at a weight of 0.3 to 0.5% by weight. Specifically, the salicylic acid may be included in the composition at a weight percentage of 0.3 to 0.5%, 0.3 to 0.45%, 0.3 to 0.4%, 0.3 to 0.35%, 0.35 to 0.5%, 0.35 to 0.45%, 0.35 to 0.45%, 0.4 to 0.5%, 0.4 to 0.45%, or 0.45 to 0.5% by weight.

[0015] When the salicylic acid is included in the antibacterial composition at 0.3 to 0.5% by weight of the total weight of the composition, the antibacterial composition, when applied to the skin, minimizes side effects such as itching and redness, and exhibits a significantly superior antibacterial effect, specifically against acne-causing bacteria. Conversely, when the salicylic acid is included in the composition at less than 0.3% by weight of the total weight of the composition, the antibacterial effect is significantly reduced; and when it is included in the composition at more than 0.5% by weight, side effects such as itching and redness increase when the composition is applied to the skin.

[0016] The "salicylic acid" is a carboxylic acid with the structure shown in Formula 1 below, equivalent to BHA (β-hydroxy acid). It promotes the softening of the stratum corneum, making it easier to exfoliate, and helps to remove sebum from pores. Therefore, it is added to cosmetics as a keratin softener. [Chemical Formula 1] The "succinic acid" is a component with the structure shown in Chemical Formula 2 below, and is found in nature, including pumpkin, some berries, mushrooms, seaweed, and fermented foods. Succinic acid is known to have anti-inflammatory and antioxidant properties, and is therefore used as an additive in cosmetics. [Chemical Formula 2] The term "antimicrobial" refers to the inhibition of the growth, development, or proliferation of all microorganisms (e.g., bacteria, fungi, etc.).

[0017] Specifically, the antibacterial activity can be the inhibition of the growth, development, or proliferation of one or more microorganisms selected from the group consisting of: Corynebacterium striatum (… Corynebacterium striatum ), Streptococcus pyogenes ( Streptococcus pyogenes ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), Bacillus cereus ( Bacillus cereus ), Micrococcus faecalis ( Micrococcus flavus Campylobacter jejuni ( Campylobacter jejuni Vibrio parahaemolyticus ( Vibrio parahaemolyticus Aspergillus niger (), Aspergillus niger Candida albicans ( Candida albicans ), Trichophyton rubrum ( Trichophyton rubrum ), Trichophyton mentagrophytes ( Trichophyton mentagrophytes ), Microsporum canis ( Microsporum canis Epidermophyton floccosum ( ), Epidermophyton floccosum ), Propionibacterium acnes ( Cutibacterium acnes Staphylococcus aureus ( Staphylococcus aureus ) and Staphylococcus epidermidis ( Staphylococcus epidermidis ).

[0018] In one specific example, the antibacterial effect may be achieved by inhibiting the growth, development, or proliferation of acne-causing bacteria.

[0019] In one specific example, the acne-causing bacteria may be one or more selected from the group consisting of Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis. Specifically, the acne-causing bacteria may be all of Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

[0020] In one specific example, the antibacterial composition can relieve acne symptoms.

[0021] In one specific example, the acne symptoms can be one or more selected from the group consisting of: open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustular vesicles. Specifically, the acne symptoms can be all of the following: open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustular vesicles.

[0022] In one experimental example, the antibacterial activity of a composition comprising salicylic acid and succinic acid against *Propionibacterium acnes*, a known acne pathogen, was confirmed. Results confirmed that Examples 1 to 3, when treated with salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, exhibited significantly superior antibacterial effects. In particular, Example 1 showed significantly superior antibacterial effects compared to Comparative Examples 1 to 3, which used a single component, and Comparative Examples 4 to 6, where the component ratio was changed to less than 1:1 or more than 1:1.9 (see Experimental Example 1).

[0023] The antibacterial composition according to one embodiment exhibits significant and excellent antibacterial effects, specifically, it exhibits excellent antibacterial effects against acne-causing bacteria. Furthermore, when the composition is applied to acne-prone skin, it can alleviate acne-related symptoms without causing side effects; therefore, the antibacterial composition according to one embodiment is effective in the prevention, relief, or treatment of acne.

[0024] In another embodiment, a pharmaceutical composition for the prevention or treatment of bacterial or fungal skin infections is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0025] The terms "salicylic acid", "succinic acid", and "acne" can be found within the aforementioned range.

[0026] Specifically, the pharmaceutical composition may comprise salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7, or 1:1.7 to 1.9.

[0027] When the pharmaceutical composition contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, it exhibits a significantly superior antibacterial effect through synergistic action compared to using a single component alone. Specifically, it shows an antibacterial effect against acne-causing bacteria, and when applied to acne-prone skin, acne symptoms are significantly reduced. On the other hand, when the pharmaceutical composition contains salicylic acid and succinic acid in a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to acne-prone skin, side effects such as itching and redness caused by salicylic acid increase. When salicylic acid and succinic acid are contained in a weight ratio greater than 1:1.9, the antibacterial effect is significantly reduced.

[0028] In one specific example, the salicylic acid may be included in the pharmaceutical composition at a weight percentage of 0.3 to 0.5%. Specifically, the salicylic acid may be included in the pharmaceutical composition at a weight percentage of 0.3 to 0.5%, 0.3 to 0.45%, 0.3 to 0.4%, 0.3 to 0.35%, 0.35 to 0.5%, 0.35 to 0.45%, 0.35 to 0.45%, 0.4 to 0.5%, 0.4 to 0.45%, or 0.45 to 0.5%.

[0029] When the salicylic acid is included in the pharmaceutical composition at a concentration of 0.3 to 0.5% by weight of the total weight of the pharmaceutical composition, the application of the pharmaceutical composition to the skin minimizes side effects such as itching and redness, and exhibits a significantly superior antibacterial effect, specifically against acne-causing bacteria. On the other hand, when the salicylic acid is included in the pharmaceutical composition at a concentration of less than 0.3% by weight of the total weight of the pharmaceutical composition, the antibacterial effect is significantly reduced, and when it is included in the pharmaceutical composition at a concentration of more than 0.5% by weight, the application of the pharmaceutical composition to the skin increases side effects such as itching and redness.

[0030] The term "bacterial or fungal infectious skin disease" refers to skin diseases caused by bacterial or fungal infections. For example, Staphylococcus aureus is a bacterium that can cause skin diseases through infection. Staphylococcus genus), Streptococcus ( Streptococcus genus), dermatobacteria ( Cutibacterium Genus), etc., fungi include Trichophyton (Trichophyton) Trichophyton Microsporum, Epidermophyton, etc.

[0031] The term "prevention" can refer to all actions that inhibit or delay the occurrence of bacterial or fungal infectious skin diseases in an individual by applying a pharmaceutical composition according to a regimen.

[0032] The term "treatment" can refer to all actions that improve or benefit an individual's symptoms of a bacterial or fungal skin infection by administering a pharmaceutical composition according to a regimen.

[0033] In addition, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers, excipients and / or diluents, thereby being provided as a pharmaceutical composition.

[0034] Specifically, the carrier can be, for example, a colloidal suspension, powder, saline, lipid, liposome, microspheres, or nanospheres. These can form complexes with or be associated with the delivery carrier and can be delivered in vivo using delivery systems known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendritic polymers, saponins, adsorption enhancers, or fatty acids.

[0035] When the pharmaceutical composition is formulated, it can be prepared using commonly used lubricants, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, fillers, extenders, binders, wetting agents, disintegrants, surfactants, and other diluents or excipients. Solid dosage forms for oral administration can include tablets, pills, powders, granules, capsules, oral films, patches, etc., which can be formulated by mixing the composition with at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid dosage forms for oral administration include suspensions, oral solutions, emulsions, syrups, etc., which can include various excipients such as wetting agents, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Formulations intended for non-oral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories, patches, etc. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate can be used. As a base for suppositories, witepsol, polyethylene glycol, Tween 61, cocoa butter, lauryl resin, glycerin gelatin, etc., can be used, and when formulated into eye drops, known diluents or excipients can be used.

[0036] The pharmaceutical composition is administered at a pharmaceutically effective amount. The term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. Effective dose levels may depend on factors including the type and severity of the patient's disease, the activity of the drug, the patient's sensitivity to the drug, the timing of administration, the route of administration and excretion rate, the duration of treatment, factors of concomitant medications, and other factors well known in the medical field. Administration may be once daily or in multiple divided doses. For example, it may be administered every other day or once a week.

[0037] The term "administration" refers to the introduction of a prescribed substance into an individual in an appropriate manner. "Individual" refers to any organism, including humans, that may be susceptible to a skin disease, such as rats, mice, pigs, horses, cattle, and livestock. As a specific example, it can be any mammal, including humans. The pharmaceutical composition can be administered orally or non-orally. For non-oral administration, the injection method can be selected from the following: topical application, patch application, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, arterial injection, intramedullary injection, intracardiac injection, intradural injection, percutaneous injection, intranasal injection, intestinal injection, local injection, sublingual injection, rectal injection, or intrapleural injection.

[0038] In one embodiment, the pharmaceutical composition may also contain other agents for treating bacterial or fungal skin infections.

[0039] The other bacterial or fungal skin disease treatment agents may be included in the pharmaceutical composition in the minimum amount that will achieve the maximum effect without side effects, which can be readily determined by those skilled in the art.

[0040] Furthermore, in one embodiment, the pharmaceutical composition can be administered alone or in combination with other known treatments for bacterial or fungal skin infections. That is, the pharmaceutical composition can be administered in combination with other treatments for bacterial or fungal skin infections, simultaneously, alone, or sequentially, and can be administered once or multiple times.

[0041] When the other bacterial or fungal skin disease treatment agents are administered in combination with the pharmaceutical composition, they can be administered at an amount or proportion that will achieve the maximum effect without side effects, which can be readily determined by those skilled in the art.

[0042] The other bacterial or fungal skin disease treatment agents may be existing known bacterial or fungal skin disease treatment agents or newly developed bacterial or fungal skin disease treatment agents.

[0043] In one specific example, the bacterial or fungal skin infection can be one or more selected from the group consisting of: acne, folliculitis, boils, psoriasis, erythema, impetigo, scabies, lymphadenitis, cellulitis, tinea, and candidiasis. More specifically, in one specific example, the bacterial or fungal skin infection can be all of the following: acne, folliculitis, boils, psoriasis, erythema, impetigo, scabies, lymphadenitis, cellulitis, tinea, and candidiasis. More specifically, the bacterial or fungal skin infection can be acne.

[0044] In one specific example, the pharmaceutical composition can inhibit the growth, development, or proliferation of bacteria or fungi. Specifically, the bacteria or fungi may be acne-causing bacteria.

[0045] In one specific example, the bacteria or fungi may be selected from one or more of the following groups: Corynebacterium banding, Streptococcus pyogenes, Pseudomonas aeruginosa, Bacillus cereus, Micrococcus flavus, Campylobacter jejuni, Vibrio parahaemolyticus, Aspergillus niger, Candida albicans, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Epidermophyton floccosum, Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

[0046] In one specific example, the bacteria or fungus may be an acne-causing pathogen. Specifically, the acne-causing pathogen may be selected from Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis (…). Staphylococcus epidermidis One or more of the following, more specifically, it can be all of Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

[0047] In one specific example, the pharmaceutical composition can prevent or treat acne symptoms.

[0048] In one specific example, the acne symptoms can be one or more selected from the group consisting of: open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustular vesicles. Specifically, the acne symptoms can be all of the following: open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustular vesicles.

[0049] The pharmaceutical composition according to one formulation exhibits significant and excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when the pharmaceutical composition is applied to acne-prone skin, it can relieve acne-related symptoms without causing side effects; therefore, the pharmaceutical composition according to one formulation is effective for the prevention, relief, or treatment of acne.

[0050] In another embodiment, an antibacterial cosmetic composition is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0051] The terms "salicylic acid", "succinic acid", "acne", and "antibacterial" can be within the aforementioned range.

[0052] Specifically, the cosmetic composition may comprise salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7, or 1:1.7 to 1.9.

[0053] When salicylic acid and succinic acid are included in the cosmetic composition in a weight ratio of 1:1 to 1.9, they exhibit significantly superior antibacterial effects through synergistic action compared to using a single ingredient alone. Specifically, they show antibacterial effects against acne-causing bacteria, and acne symptoms are significantly reduced when applied to acne-prone skin. On the other hand, when salicylic acid and succinic acid are included in the cosmetic composition in a weight ratio less than 1:1, the antibacterial effect is significantly reduced, and side effects such as itching and redness caused by salicylic acid increase when applied to acne-prone skin. When salicylic acid and succinic acid are included in a weight ratio greater than 1:1.9, the antibacterial effect is significantly reduced.

[0054] In one specific example, the salicylic acid may be included in the cosmetic composition at a weight percentage of 0.3 to 0.5%. Specifically, the salicylic acid may be included in the cosmetic composition at a weight percentage of 0.3 to 0.5%, 0.3 to 0.45%, 0.3 to 0.4%, 0.3 to 0.35%, 0.35 to 0.5%, 0.35 to 0.45%, 0.35 to 0.45%, 0.4 to 0.5%, 0.4 to 0.45%, or 0.45 to 0.5%.

[0055] When the salicylic acid is included in the cosmetic composition at a weight of 0.3 to 0.5% by weight of the total weight of the cosmetic composition, side effects such as itching and redness are minimized when the cosmetic composition is applied to the skin, and a significantly superior antibacterial effect is observed, specifically against acne-causing bacteria. On the other hand, when the salicylic acid is included in the cosmetic composition at a weight of less than 0.3% by weight of the total weight of the cosmetic composition, the antibacterial effect is significantly reduced, and when it is included in the cosmetic composition at a weight of more than 0.5% by weight, side effects such as itching and redness increase when the cosmetic composition is applied to the skin.

[0056] In one specific example, the antibacterial effect may be achieved by inhibiting the growth, development, or proliferation of acne-causing bacteria.

[0057] In one specific example, the cosmetic composition can relieve acne symptoms.

[0058] The cosmetic composition can also be prepared in any dosage form commonly prepared in the technical field to which this invention pertains. For example, it can be formulated as a toner, nourishing water, lotion, moisturizing emulsion, face cream, ointment, gel, solution, suspension, oil, wax, mask, loose powder, foundation, spray, surfactant-containing cleanser, patch, etc. More specifically, it can be formulated as astringent, lotion, softening lotion, toner, body cream, moisturizing lotion, loose powder, serum, eye cream, sunscreen, sunscreen cream, makeup primer, makeup base cream, BB cream, pressed powder, liquid foundation, makeup remover, facial foam, makeup remover water, soap, mask, stick product, balm-type product, patch, spray, or powder, etc.

[0059] The cosmetic composition may also contain any conventional cosmetic ingredient selected from commonly used cosmetic additives, such as thickeners, dispersants, fragrances, fillers, preservatives, neutralizers, sweeteners, vitamins, free radical scavengers, metal ion chelators, functional ingredients, and mixtures thereof. Those skilled in the art can select any additive and / or its amount so that the advantageous properties of the composition according to this specification are not or substantially not adversely affected by the intended addition.

[0060] When the cosmetic composition is a surfactant-containing cleanser, the carrier component may also include fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinate monoesters, hydroxyethyl sulfonates, imidazoline derivatives, methyl taurine, sarcosinate, fatty acid amide ether sulfates, alkylamide betaine, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters, etc.

[0061] When the cosmetic composition is in the form of a cream or gel, it may also contain animal oil, vegetable oil, wax, paraffin, starch, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide as a carrier.

[0062] When the cosmetic composition is a solution or emulsion formulation, it may also contain water, ethanol, isopropanol, diethyl carbonate, ethyl acetate, benzyl alcohol, propylene glycol, glycerol aliphatic esters, polyethylene glycol, or sorbitan fatty acid esters as solvents, solvators, or emulsifiers.

[0063] When the cosmetic composition is a suspension formulation, the carrier component may also include liquid diluents (such as water, ethanol or propylene glycol), suspending agents (such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester and polyoxyethylene sorbitan ester), microcrystalline cellulose, aluminum hydroxide, bentonite, agar or tragacanth gum, etc.

[0064] When the cosmetic composition is in the form of a powder or a spray, the carrier component may also include lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder. In particular, when it is in the form of a spray, it may further include propellants such as chlorofluorocarbons, propane / butane, or dimethyl ether.

[0065] The cosmetic composition can be applied alone or repeatedly, or layered with other cosmetic compositions. Furthermore, the cosmetic composition can be used according to conventional methods, and the frequency of application can be adjusted according to the user's skin condition or preference.

[0066] The cosmetic composition according to one embodiment exhibits significant and excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when the cosmetic composition is applied to acne-prone skin, it can alleviate acne-related symptoms without causing side effects; therefore, the cosmetic composition according to one embodiment is effective in the prevention, relief, or treatment of acne.

[0067] In another embodiment, an antibacterial topical skin agent is provided, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0068] The terms "salicylic acid", "succinic acid", "acne", and "antibacterial" can be within the aforementioned range.

[0069] Specifically, the topical skin agent may contain salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7, or 1:1.7 to 1.9.

[0070] When the topical skin agent contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, it exhibits a significantly superior antibacterial effect through synergistic action compared to using a single ingredient alone. Specifically, it shows an antibacterial effect against acne-causing bacteria, and acne symptoms are significantly reduced when applied to acne-prone skin. On the other hand, when the topical skin agent contains salicylic acid and succinic acid in a weight ratio less than 1:1, the antibacterial effect is significantly reduced, and side effects such as itching and redness caused by salicylic acid increase when applied to acne-prone skin. When the weight ratio of salicylic acid and succinic acid exceeds 1:1.9, the antibacterial effect is significantly reduced.

[0071] In one specific example, the salicylic acid may be included in the total weight of the topical skin agent at 0.3 to 0.5% by weight. Specifically, the salicylic acid may be included in the total weight of the topical skin agent at 0.3 to 0.5% by weight, 0.3 to 0.45% by weight, 0.3 to 0.4% by weight, 0.3 to 0.35% by weight, 0.35 to 0.5% by weight, 0.35 to 0.45% by weight, 0.35 to 0.45% by weight, 0.4 to 0.5% by weight, or 0.45 to 0.5% by weight.

[0072] When the salicylic acid is included in the topical skin agent at 0.3 to 0.5% by weight of the total weight of the agent, side effects such as itching and redness are minimized when the agent is applied to the skin, and a significantly superior antibacterial effect is observed, specifically against acne-causing bacteria. Conversely, when the salicylic acid is included in the topical skin agent at less than 0.3% by weight of the total weight of the agent, the antibacterial effect is significantly reduced; and when it is included in the topical skin agent at more than 0.5% by weight, side effects such as itching and redness increase when the agent is applied to the skin.

[0073] In one specific example, the antibacterial effect may be achieved by inhibiting the growth, development, or proliferation of acne-causing bacteria.

[0074] In one specific example, the topical skin agent can relieve acne symptoms.

[0075] The topical skin agent may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, medicated bandage, lotion, shampoo, conditioner, conditioning agent, hair mask, or a combination thereof. The topical skin agent may be appropriately combined with ingredients commonly used in cosmetics or pharmaceuticals, such as aqueous components, oil-based components, powder components, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof. The topical skin preparation may also be appropriately combined with metal chelating agents such as disodium EDTA, trisodium EDTA, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannins, verapamil, licorice extract, glycyrrhizin, hot water extract of calin fruit, various herbs, tocopheryl acetate, glycyrrhetinic acid, tranexamic acid and its derivatives or salts; and sugars such as vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.

[0076] The topical skin agent according to one formulation exhibits significant and excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when applied to acne-prone skin, the topical skin agent can alleviate acne-related symptoms without causing side effects; therefore, the topical skin agent according to one formulation is effective for the prevention, relief, or treatment of acne.

[0077] In another embodiment, a multilayer patch is provided, comprising: an antibacterial layer containing salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; and A coating is provided on the first surface of the antibacterial layer and comprises thermoplastic polyurethane (TPU).

[0078] The terms "salicylic acid", "succinic acid", "acne", and "antibacterial" can be within the aforementioned range.

[0079] In one specific example, the coating may be composed of thermoplastic polyurethane.

[0080] Specifically, the patch may contain salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7, or 1:1.7 to 1.9.

[0081] When the patch contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, it exhibits a significantly superior antibacterial effect through synergistic action compared to using a single ingredient alone. Specifically, it demonstrates antibacterial activity against acne-causing bacteria, and acne symptoms are significantly reduced when applied to acne-prone skin. Conversely, when the patch contains salicylic acid and succinic acid in a weight ratio less than 1:1, the antibacterial effect is significantly reduced, and side effects such as itching and redness caused by salicylic acid increase when applied to acne-prone skin. Furthermore, when the weight ratio of salicylic acid and succinic acid exceeds 1:1.9, the antibacterial effect is significantly reduced.

[0082] In one specific example, the salicylic acid may be included in the antibacterial layer at a concentration of 0.3 to 0.5% by weight. Specifically, the salicylic acid may be included in the antibacterial layer at a concentration of 0.3 to 0.5% by weight, 0.3 to 0.45% by weight, 0.3 to 0.4% by weight, 0.3 to 0.35% by weight, 0.35 to 0.5% by weight, 0.35 to 0.45% by weight, 0.35 to 0.45% by weight, 0.4 to 0.5% by weight, or 0.45 to 0.5% by weight.

[0083] When the salicylic acid is included in the patch at 0.3 to 0.5% by weight of the total antibacterial layer, side effects such as itching and redness are minimized when the patch is applied to the skin, and a significantly superior antibacterial effect is observed, specifically against acne-causing bacteria. Conversely, when the salicylic acid is included in the patch at less than 0.3% by weight of the total antibacterial layer, the antibacterial effect is significantly reduced; and when it is included in the patch at more than 0.5% by weight, side effects such as itching and redness increase when the patch is applied to the skin.

[0084] In one specific example, the antibacterial layer may have activity that inhibits the growth, development, or proliferation of enzymes that cause acne.

[0085] In one specific example, the antibacterial layer may be a hydrogel.

[0086] The "hydrogel" is a substance with a three-dimensional network structure formed by the cross-linking of hydrophilic polymers. This three-dimensional structure can contain a large amount of water, exhibiting physicochemical properties equivalent to an intermediate state between liquid and solid.

[0087] In one specific example, the hydrogel may be cross-linked from hydrophilic polymers.

[0088] The "cross-linking" refers to a chemical reaction that connects polymer chains through chemical bonds (covalent bonds, non-covalent bonds, etc.). For example, if hydrophilic polymers form cross-links, the polymer chains will connect to each other like a network, thus forming a three-dimensional network structure.

[0089] In one specific example, the hydrophilic polymer may be one or more selected from the group consisting of: carboxymethyl cellulose, gelatin, collagen, pectin, ethyl cellulose, methyl cellulose, polyether, hydroxypropylmethylcellulose, sodium carboxymethyl cellulose, xanthan gum, and alginate. Specifically, the hydrophilic polymer may be carboxymethyl cellulose.

[0090] In one specific example, the antimicrobial layer may also include an adhesive.

[0091] In one specific example, the adhesive may be one or more selected from the group consisting of: hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), poloxamer 407, rosin, ethylene glycol rosinate, glyceryl rosinate, pentaerythritol rosinate, and hydrogenated rosinate. Rosinate, polyvinylpyrrolidone, and polyvinylpyrrolidone / vinyl acetate copolymer.

[0092] Specifically, the adhesive may be selected from one or more of the following: hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), and poloxamer 407. More specifically, the adhesive may be all of the following: hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydrocinnamate, polyethylene glycol (PEG), and poloxamer 407.

[0093] When the "antibacterial layer" contains salicylic acid and succinic acid and is applied to the skin, it releases the salicylic acid and succinic acid, thereby inhibiting the growth, development, or proliferation of microorganisms present on the skin, specifically acne-causing bacteria. Specifically, the surface of the antibacterial layer that adheres to the skin is the second surface, and the first surface is the surface opposite the second surface of the antibacterial layer, and is coated with a coating layer.

[0094] Furthermore, the antibacterial layer further contains a hydrocolloid component, which absorbs exudates from microbial infections, wounds, etc., and creates a moist environment, thereby promoting skin regeneration, protecting wounds, and preventing infection. Additionally, the antibacterial layer further contains an adhesive component, ensuring that the patch adheres to the skin without shifting.

[0095] The "coating" is a layer present on the first surface of the antibacterial layer, sealing the first surface of the antibacterial layer—the surface facing outwards rather than the skin—so that the salicylic acid and succinic acid present in the antibacterial layer can be released onto the skin only through the second surface, thereby protecting the acne-affected areas. Furthermore, the TPU contained in the coating has the advantage of being thin and inconspicuous even when applied to the skin.

[0096] In one specific example, the patch is disposed on the second surface of the antibacterial layer and may further include a release film layer comprising polyethylene terephthalate (PET). Specifically, the patch may further include a release film layer composed of polyethylene terephthalate (PET).

[0097] The "release film" is a layer placed on the skin-attached surface, i.e., the second surface of the antibacterial layer, when the patch is actually applied to the skin. Before use, it prevents the release of salicylic acid and succinic acid from the antibacterial layer to the outside and protects the adhesive surface of the antibacterial layer from external influences, thereby ensuring hygienic use and maintaining adhesion. In addition, it also facilitates the peeling off of the patch before use.

[0098] In one specific example, the thickness of the patch can be from 0.225 to 0.275 mm. Specifically, the thickness of the patch can be 0.225 to 0.275 mm, 0.225 to 0.255 mm, 0.225 to 0.245 mm, 0.225 to 0.235 mm, 0.235 to 0.275 mm, 0.235 to 0.255 mm, 0.235 to 0.245 mm, 0.245 to 0.275 mm, 0.245 to 0.255 mm, or 0.255 to 0.275 mm.

[0099] Specifically, the thickness of the patch refers to the thickness of the patch consisting of a coating and an antibacterial layer.

[0100] When the thickness of the patch is between 0.225 and 0.275 mm, the patch is very thin when applied to the skin, making its attachment position inconspicuous. It adheres well even on curved skin surfaces without localized detachment. On the other hand, when the thickness of the patch is less than 0.225 mm, it is too thin and prone to tearing. When it exceeds 0.275 mm, the attachment position becomes more noticeable, and the increased thickness makes it more likely to detach on curved skin surfaces.

[0101] In one specific example, the tensile strength of the patch can be from 1400 to 1700 g.f / 12 mm. Specifically, the tensile strength of the patch can be 1400 to 1700 g.f / 12 mm, 1400 to 1600 g.f / 12 mm, 1400 to 1500 g.f / 12 mm, 1400 to 1450 g.f / 12 mm, 1450 to 1700 g.f / 12 mm, 1450 to 1600 g.f / 12 mm, 1450 to 1500 g.f / 12 mm, 1500 to 1700 g.f / 12 mm, 1500 to 1600 g.f / 12 mm, or 1600 to 1700 g.f / 12 mm.

[0102] The term "tensile strength" refers to the maximum force that the patch can withstand without breaking when subjected to tensile force. When the tensile strength of the patch is between 1400 and 1700 g.f / 12 mm, the patch will not tear when peeled from the release liner for use and exhibits excellent durability. On the other hand, when the tensile strength of the patch is less than 1400 g.f / 12 mm, the patch may tear easily, and when it exceeds 1700 g.f / 12 mm, it may be too stiff and easily break.

[0103] In one specific example, the adhesive force of the patch can be 500 to 600 g.f / 12 mm. Specifically, the adhesive force of the patch can be 500 to 600 g.f / 12 mm, 500 to 570 g.f / 12 mm, 500 to 550 g.f / 12 mm, 500 to 530 g.f / 12 mm, 530 to 600 g.f / 12 mm, 530 to 570 g.f / 12 mm, 530 to 550 g.f / 12 mm, 550 to 600 g.f / 12 mm, 550 to 570 g.f / 12 mm, or 570 to 600 g.f / 12 mm.

[0104] The term "adhesion" refers to the ability of the patch to adhere to the skin without detaching when a certain force is applied. When the adhesion of the patch is 500 to 600 g.f / 12mm, the patch is less likely to detach over time and maintains stable adhesion even on curved surfaces of the skin. On the other hand, when the adhesion of the patch is less than 500 g.f / 12mm, the patch is prone to detachment and cannot adhere to the skin. When it exceeds 600 g.f / 12mm, the patch will not detach from the skin, which may cause skin damage when removing the patch.

[0105] In one specific example, the absorbance of the patch can be 550 to 650% (24 hours, g / cm³). 2 Specifically, the absorbance of the patch can be 550 to 650% (24 hours, g / cm³). 2 ), 550 to 630% (24 hours, g / cm³) 2 ), 550 to 610% (24 hours, g / cm³) 2 ), 550 to 580% (24 hours, g / cm³) 2 ), 580 to 650% (24 hours, g / cm³) 2 ), 580 to 630% (24 hours, g / cm³) 2 ), 580 to 610% (24 hours, g / cm³) 2 ), 610 to 650% (24 hours, g / cm³) 2 ), 610 to 630% (24 hours, g / cm³) 2 ) or 630 to 650% (24 hours, g / cm³) 2 ).

[0106] The term "absorption rate" refers to the patch's ability to absorb and retain moisture. For example, when a patch is applied to a wound, it refers to its ability to retain exudates (plasma proteins, water, platelets, white blood cells, enzymes, etc.) produced by the wound.

[0107] When the absorbance of the patch is 550 to 650% (24 hours, g / cm³), 2 When the patch absorbs exudate produced by the skin, it creates a moist environment and helps heal wounds caused by acne-causing bacteria. On the other hand, when the absorption rate of the patch is less than 550% (24 hours, g / cm³), 2 When the patch fails to absorb exudate from the skin wound, it leaks outwards, exceeding 650% (24 hours, g / cm³). 2 When this happens, the excessively moist environment can weaken or damage the surrounding skin.

[0108] In one experimental example, the physical properties of the patch were evaluated. Measurements confirmed that, with a thickness of 0.230 mm, a tensile strength of 1496.90 gf / 12 mm, an adhesion strength of 543.00 gf / 12 mm, and a strength of 615.00% (24 hours, g / cm³), the patch achieved the desired physical properties. 2 When applied to the skin, the absorbent material is thin and its application position is inconspicuous. It is also not easily torn and has the property of being able to adhere stably to the skin, absorb exudate from wounds, and thus create a moist environment (see Experimental Example 2).

[0109] The patch according to one formulation exhibits significant and excellent antibacterial effects, specifically, it demonstrates excellent antibacterial effects against acne-causing bacteria. Furthermore, when the patch is applied to acne-prone skin, it can relieve acne-related symptoms without causing side effects; therefore, the patch according to one formulation is effective for the prevention, relief, or treatment of acne.

[0110] Invention Effects Antibacterial compositions containing salicylic acid and succinic acid exhibit superior antibacterial effects compared to single-component formulations due to the synergistic effect between the two components, particularly against acne-causing bacteria. Furthermore, when applied to acne-prone skin, the compositions demonstrate preventative, alleviating, or therapeutic effects on acne-related symptoms without side effects. Attached Figure Description

[0111] Figure 1 This diagram illustrates the layers of an acne patch, which consists of a multi-layered structure.

[0112] Figure 2 The graph shows the results of the antibacterial effect after treating Propionibacterium acnes with the positive control group (ampicillin) and Examples 1 to 3, respectively.

[0113] Figure 3 The graph shows the results of the antibacterial effect after treating Propionibacterium acnes with Comparative Examples 1 to 6.

[0114] Figure 4 The image shows a photograph of the actual fabricated patch of the present invention. Figure 5 The image shows a photograph of an actual prepared patch of the present invention applied to the skin. Detailed Implementation

[0115] The present invention will be described in more detail below through embodiments. However, these embodiments are intended to illustrate the invention, and the scope of the invention is not limited to these embodiments.

[0116] <Preparation Example 1> Preparation of a composition containing salicylic acid and succinic acid. Compositions containing salicylic acid and succinic acid were prepared by mixing powders according to the composition shown in Table 1 below.

[0117] Table 1 <Preparation Example 2> Preparation of acne patches containing salicylic acid and succinic acid like Figure 1 As shown, the preparation of the acne patch, which consists of three layers, is as follows.

[0118] The layers that make up the patch are as follows: - Coating: Contains TPU - Antibacterial layer: Contains antibacterial components, adhesives, and hydrocolloid components. - Release film: Contains PET.

[0119] Specifically, according to the composition in Table 2 below, a mixture of the adhesive components—hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, and pentaerythritol tetra(bis-tert-butylhydroxyhydrogenated cinnamic acid) ester—was stirred at 130 to 160°C at 5 to 10 rpm for 45 minutes to completely dissolve the mixture. Then, cellulose gum was added to the mixture, and after stirring at 130 to 160°C at 5 to 10 rpm for 3 hours to completely disperse all components, salicylic acid and succinic acid were added, and the mixture was stirred at 130 to 160°C at 5 to 10 rpm for 60 minutes to prepare a solution for the antibacterial film.

[0120] Subsequently, the solution used to prepare the antibacterial layer was stirred at 110°C and 20 rpm for 30 minutes under vacuum, and then stirred at 5 rpm for 100 minutes to perform a degassing process.

[0121] After the degassing process, the degassing solution is washed at 135°C and transferred to a storage tank, where it is stored at 140±10°C. It is then coated onto a TPU film as a coating layer, and prepared by die-cutting. A release film layer—a PET film—can be added during commercialization to protect the adhesive surface of the antibacterial layer.

[0122] Table 2 <Experimental Example 1> Determination of antibacterial effect (paper disc diffusion method) To confirm the acne prevention, improvement, or treatment effects of Examples 1 to 3 and Comparative Examples 1 to 6 prepared in Preparation Example 1, the antibacterial effect of Propionibacterium acnes was evaluated.

[0123] Specifically, 100 μL each of Examples 1 to 3 and Comparative Examples 1 to 6 were impregnated onto sterile paper discs, dried for 30 minutes, and then placed on culture media. Inoculation was then carried out. C.acnes (Inoculation dose: 1×10) 4 Up to 1×105 The culture medium (CFU / ml) was poured in and allowed to solidify, then incubated at 35±2.5℃ for 24 hours. Afterwards, the size of the inhibition zone formed around the paper disc was measured. Ampicillin, a known antibacterial agent, was used as a positive control; an inhibition zone of 14.7 mm was observed with ampicillin.

[0124] like Figure 2 , Figure 3 As shown in Table 3 below, Examples 1 to 3 all showed inhibition zones of more than 11.6 mm and exhibited excellent anti-acne bacteria activity. For Example 1, it showed an inhibition zone similar to that of ampicillin used as a positive control group, confirming its significant and excellent anti-acne bacteria effect.

[0125] On the other hand, for the single-component comparative examples 1 to 3, even when treated at concentrations of 2% or 4%, which are equivalent to more than 2.2 times the concentrations of examples 1 to 3, the size of their inhibition zones was smaller than that of example 1, and they showed a similar level of size to examples 2 and 3. When the ratio of salicylic acid to succinic acid was 1:2 or higher (comparative example 4) or 1.25 to 1.57:1 (comparative examples 5 and 6), they showed inhibition zones of 10 to 10.6 mm, indicating a lower anti-acne bacteria effect.

[0126] The results confirm that when salicylic acid and succinic acid are mixed in the proportions shown in Examples 1 to 3, they exhibit a significant and excellent anti-acne bacteria effect through synergistic action.

[0127] Table 3 <Experimental Example 2> Determination of the physical properties (thickness, tensile strength, adhesion, and absorption rate) of acne patches Based on the results of Experiment 1, it was confirmed that when salicylic acid and succinic acid are mixed, specifically, when the proportion of succinic acid is higher than that of salicylic acid and the ratio of salicylic acid to succinic acid is less than 1:2, a significant and excellent effect on the prevention, improvement or treatment of acne is exhibited through synergistic effect.

[0128] Therefore, a patch containing a mixture of salicylic acid and succinic acid was prepared according to Preparation Example 2, and it was confirmed whether it exhibited physical properties (thickness, tensile strength, adhesion and absorption rate) suitable for actual application to the skin.

[0129] Specifically, the thickness was measured using a vernier caliper (Mitudoyo), the patch was placed between test fixtures using a rheometer (Brookfield), and the fixture separation speed was set to 500±50 mm / min. The tensile strength was then measured by measuring the maximum 10% elongation at break.

[0130] For adhesion, a patch with a width of 24±0.5 mm and a length of 100 mm was placed at one end of a stainless steel panel and pressed down to about 30 mm using a rubber roller with a weight of 2040±45 g. The patch and panel were then placed on a testing machine at 180° and stretched at a crosshead speed of 5±0.5 mm / s to measure the load. The load at 12 mm was calculated and evaluated.

[0131] For absorption rate, the weight of the petri dish (W1) and the weight of the 5×5cm patch (W2) were measured. After placing the patch on the petri dish, preheated distilled water (40 times the sample weight) was added to the petri dish, and the mixture was left to stand at 37±1℃ for 24 hours. Then, only the distilled water was removed from the petri dish, and the weight was measured (W3). The specific calculation method is as follows: [Mathematical Expression 1] Absorption rate = (W3 – W1 – W2) / W2 × 100.

[0132] As shown in Table 4 below, the thickness of patch 1 is 0.230 mm, which meets the target specification of 0.225 mm to 0.275 mm for thin application to the skin, and the tensile strength is 1496.90 gf / 12 mm, which meets the minimum target specification of 1000 gf / 12 mm for patches that are not easily torn or broken, thus confirming its excellent durability.

[0133] Furthermore, patch 1 has an adhesion of 543.00 gf / 12 mm, which meets the minimum target specification of 150 gf / 12 mm, thus confirming that it can adhere well to the skin without falling off.

[0134] The patch 1 is a hydrocolloid patch that provides a humid environment; therefore, its absorption rate was also measured. The results showed that the absorption rate of patch 1 reached 615.00% (24 hours, g / cm³). 2 ), meeting the minimum target specification of 100% (24 hours, g / cm³) for absorbing exudate from skin wounds, etc. 2 This confirms that it has a high absorption rate.

[0135] The results confirm that the patch 1 containing a mixture of salicylic acid and succinic acid exhibits excellent physical properties (thinness, high tensile strength, strong adhesion and high absorption rate) as an acne patch.

[0136] Table 4

Claims

1. An antibacterial composition, characterized in that, It contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

2. The antibacterial composition according to claim 1, characterized in that, The salicylic acid is included in the composition at a weight of 0.3 to 0.5% by weight of the total weight of the antibacterial composition.

3. The antibacterial composition according to claim 1, characterized in that, The antibacterial effect is achieved by inhibiting the growth, development, or proliferation of acne-causing bacteria.

4. The antibacterial composition according to claim 3, characterized in that, The acne-causing bacteria are selected from one or more of the following groups: Propionibacterium acnes (… Cutibacterium acnes Staphylococcus aureus ( Staphylococcus aureus ) and Staphylococcus epidermidis ( Staphylococcus epidermidis ).

5. The antibacterial composition according to claim 1, characterized in that, The antibacterial composition relieves acne symptoms.

6. The antibacterial composition according to claim 5, characterized in that, The acne symptoms are selected from one or more of the following groups: open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and purulent vesicles.

7. A pharmaceutical composition for the prevention or treatment of bacterial or fungal skin infections, characterized in that, It contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

8. An antibacterial cosmetic composition, characterized in that, It contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

9. An antibacterial topical skin agent, characterized in that, It contains salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

10. A multi-layer patch, characterized in that, include: An antimicrobial layer comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; as well as A coating, wherein the coating is disposed on a first surface of the antibacterial layer and comprises thermoplastic polyurethane.

11. The patch according to claim 10, characterized in that, It also includes a release film layer, which is disposed on the second surface of the antibacterial layer and contains polyethylene terephthalate.

12. The patch according to claim 10, characterized in that, The antibacterial layer is a hydrogel.

13. The patch according to claim 12, characterized in that, The hydrogel is composed of cross-linked hydrophilic polymers.

14. The patch according to claim 13, characterized in that, The hydrophilic polymer is selected from one or more of the following groups: carboxymethyl cellulose, gelatin, collagen, pectin, ethyl cellulose, methyl cellulose, polyether, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, xanthan gum, and alginate.

15. The patch according to claim 10, characterized in that, The antimicrobial layer also includes an adhesive.

16. The patch according to claim 15, characterized in that, The adhesive is selected from one or more of the following groups: hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, pentaerythritol tetra(bis-tert-butylhydroxyhydrogenated cinnamic acid) ester, polyethylene glycol, poloxamer 407, rosin, ethylene glycol rosin ester, glyceryl rosin ester, pentaerythritol rosin ester, hydrogenated rosin ester, polyvinylpyrrolidone, and polyvinylpyrrolidone / vinyl acetate copolymer.

17. The patch according to claim 10, characterized in that, The thickness of the patch is 0.225 to 0.275 mm.

18. The patch according to claim 10, characterized in that, The tensile strength of the patch is 1400 to 1700 g.f / 12 mm.

19. The patch according to claim 10, characterized in that, The adhesion of the patch is 500 to 600 g·f / 12 mm.

20. The patch according to claim 10, characterized in that, The patch has an absorption rate of 550 to 650% (24 hours, g / cm³). 2 ).

Images